scholarly article | Q13442814 |
P2093 | author name string | Lu Y | |
Schmidt AM | |||
Stern D | |||
Lee KJ | |||
Chow WS | |||
Park L | |||
Ferran LJ Jr | |||
Raman KG | |||
P2860 | cites work | ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree | Q72689998 |
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells | Q28509783 | ||
THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM | Q29391553 | ||
Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E | Q29615236 | ||
Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications | Q34049428 | ||
The role of lipid peroxidation and antioxidants in oxidative modification of LDL. | Q35379559 | ||
Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications | Q35661794 | ||
Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins | Q35748423 | ||
Glucose and diabetic vascular disease. | Q36379991 | ||
Quantitative assessment of atherosclerotic lesions in mice | Q36456167 | ||
Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. | Q37308593 | ||
Increased atherosclerosis in streptozotocin-induced diabetic mice | Q37353969 | ||
Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of dia | Q38292287 | ||
Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats | Q39759463 | ||
The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyl | Q39770000 | ||
Streptozotocin-Induced Pancreatic Insulitis: New Model of Diabetes Mellitus | Q39998473 | ||
The role of oxidized lipoproteins in atherogenesis | Q41043422 | ||
Diabetes and cardiovascular disease. The Framingham study | Q41509493 | ||
Effect of the Antioxidant N,N′ -Diphenyl 1,4-Phenylenediamine (DPPD) on Atherosclerosis in ApoE-Deficient Mice | Q41671565 | ||
Is hyperglycemia associated with cardiovascular disease? The Framingham Study | Q41762879 | ||
Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits | Q45252141 | ||
Activation of the Receptor for Advanced Glycation End Products Triggers a p21 -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress | Q50180621 | ||
5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. | Q51615365 | ||
Metabolic control in 131 juvenile-onset diabetic patients as measured by HbA1c: relation to age, duration, C-peptide, insulin dose, and one or two insulin injections. | Q51650530 | ||
A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection | Q59068486 | ||
The dark side of glucose | Q71563592 | ||
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | atherosclerosis | Q12252367 |
P304 | page(s) | 1025-1031 | |
P577 | publication date | 1998-09-01 | |
P1433 | published in | Nature Medicine | Q1633234 |
P1476 | title | Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts | |
P478 | volume | 4 |
Q38759194 | 2016 ATVB Plenary Lecture: Receptor for Advanced Glycation Endproducts and Implications for the Pathogenesis an Treatment of Cardiometabolic Disorders: Spotlight on the Macrophage |
Q91960865 | A Receptor of the Immunoglobulin Superfamily Regulates Adaptive Thermogenesis |
Q38271792 | A new glycation product 'norpronyl-lysine,' and direct characterization of cross linking and other glycation adducts: NMR of model compounds and collagen |
Q28507626 | A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis |
Q48103881 | ADAM10 modulates calcitriol-regulated RAGE in cardiomyocytes |
Q51747235 | AGE-RAGE Stress, Stressors, and Antistressors in Health and Disease. |
Q36844673 | AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice |
Q52790388 | AGER gene polymorphisms and soluble receptor for advanced glycation end product in patients with idiopathic pulmonary fibrosis. |
Q38213275 | AGEs and chronic subclinical inflammation in diabetes: disorders of immune system |
Q38116590 | AGEs, contributors to placental bed vascular changes leading to preeclampsia |
Q46734928 | AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. |
Q43710091 | Activation of MAPK by modified low-density lipoproteins in vascular smooth muscle cells |
Q39883888 | Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice |
Q35086500 | Activation of the receptor for advanced glycation end products induces nuclear inhibitor of protein phosphatase-1 suppression |
Q59703917 | Adenovirus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor (SR-AI) in LDL receptor knock-out mice |
Q93355257 | Advanced Glycation End Products Stimulate Angiotensinogen Production in Renal Proximal Tubular Cells |
Q26774333 | Advanced Glycation End Products: Link between Diet and Ovulatory Dysfunction in PCOS? |
Q35796793 | Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovascular disease |
Q41682122 | Advanced glycation end products (AGEs) activate mast cells |
Q40789629 | Advanced glycation end products (AGEs)-induced expression of TGF-beta 1 is suppressed by a protease in the tubule cell line LLC-PK1. |
Q37433970 | Advanced glycation end products and C-peptide-modulators in diabetic vasculopathy and atherogenesis |
Q36069797 | Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation |
Q34579585 | Advanced glycation end products and vascular structure and function |
Q34542291 | Advanced glycation end products in infant formulas do not contribute to insulin resistance associated with their consumption |
Q30445160 | Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway |
Q44947212 | Advanced glycation end products potentiate the stimulatory effect of glucose on macrophage lipoprotein lipase expression |
Q36974285 | Advanced glycation end products, diabetes and ageing. |
Q37780646 | Advanced glycation end products, oxidative stress and diabetic nephropathy |
Q38081119 | Advanced glycation end products: role in pathology of diabetic cardiomyopathy |
Q35672476 | Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease |
Q37801314 | Advanced glycation endproducts: from precursors to RAGE: round and round we go. |
Q35409645 | Age-related vascular stiffening: causes and consequences. |
Q36099419 | Agents in development for the treatment of diabetic nephropathy |
Q35133201 | Aldose reductase (AKR1B3) regulates the accumulation of advanced glycosylation end products (AGEs) and the expression of AGE receptor (RAGE). |
Q35090344 | Aldose reductase and AGE-RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats. |
Q36543639 | Aldose reductase protects against early atherosclerotic lesion formation in apolipoprotein E-null mice |
Q38863647 | Altered Expression of NF- κ B and SP1 after Exposure to Advanced Glycation End-Products and Effects of Neurotrophic Factors in AGEs Exposed Rat Retinas. |
Q37233185 | Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene |
Q37609701 | An inverse association between serum soluble receptor of advanced glycation end products and hyperandrogenism and potential implication in polycystic ovary syndrome patients |
Q38001410 | An update on advanced glycation endproducts and atherosclerosis |
Q40021400 | Analysis and biological relevance of advanced glycation end-products of DNA in eukaryotic cells |
Q46103013 | Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes. |
Q26822630 | Animal models of diabetic macrovascular complications: key players in the development of new therapeutic approaches |
Q34067128 | Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm |
Q34355358 | Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes |
Q41886031 | Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond. |
Q41202872 | Arterial calcification is driven by RAGE in Enpp1-/- mice |
Q41504461 | Articular chondrocytes express the receptor for advanced glycation end products: Potential role in osteoarthritis |
Q37235902 | Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. |
Q80253430 | Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes |
Q35152739 | Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study |
Q34949171 | Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS) |
Q34107554 | Atherosclerosis and diabetes: the RAGE connection |
Q28303607 | Atherosclerosis and restenosis: is there a role for RAGE? |
Q36909193 | Atherosclerosis and the Hypercholesterolemic AGE-RAGE Axis |
Q36857541 | Atherosclerosis in diabetes and insulin resistance |
Q34269548 | Atorvastatin inhibits the expression of RAGE induced by advanced glycation end products on aortas in healthy Sprague-Dawley rats |
Q40802125 | Below the radar: advanced glycation end products that detour "around the side". Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes? |
Q39199900 | Beneficial Effect of Glucose Control on Atherosclerosis Progression in Diabetic ApoE(-/-) Mice: Shown by Rage Directed Imaging. |
Q29012485 | Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy |
Q28131781 | Biochemistry and molecular cell biology of diabetic complications |
Q54967677 | Blockade of HMGB1 Attenuates Diabetic Nephropathy in Mice. |
Q34432623 | Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice |
Q41893958 | Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. |
Q35825346 | Bone fragility in type 2 diabetes mellitus |
Q35135006 | Bone marrow-derived mesenchymal stem cells improve the functioning of neurotrophic factors in a mouse model of diabetic neuropathy |
Q37056305 | Bone metabolism and fracture risk in type 2 diabetes mellitus |
Q38502595 | Cell Interactions with Vascular Regenerative MAA-Based Materials in the Context of Wound Healing |
Q43257049 | Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF-beta in a murine diabetic model of atherosclerosis |
Q33971339 | Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid beta-peptide |
Q38831558 | Cellular mechanisms and consequences of glycation in atherosclerosis and obesity |
Q34890522 | Central role of RAGE-dependent neointimal expansion in arterial restenosis |
Q24310573 | Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15 |
Q35882416 | Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products |
Q42067799 | Ciprofloxacin inhibits advanced glycation end products-induced adhesion molecule expression on human monocytes |
Q51742202 | Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. |
Q54764181 | Circulating levels of soluble receptor for advanced glycation end product are inversely associated with vascular calcification in patients on haemodialysis independent of S100A12 (EN-RAGE) levels. |
Q47948668 | Circulating soluble RAGE isoforms are attenuated in obese, impaired-glucose-tolerant individuals and are associated with the development of type 2 diabetes |
Q58947783 | Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease |
Q54941926 | Clinical and Biological Predictors of Plasma Levels of Soluble RAGE in Critically Ill Patients: Secondary Analysis of a Prospective Multicenter Observational Study. |
Q34048575 | Clinical features of schizophrenia with enhanced carbonyl stress. |
Q37875591 | Clinical science review article: understanding the implications of diabetes on the vascular system |
Q44037770 | Cloning and characterization of soluble decoy receptors |
Q35787903 | Cloning and expression of the rat nephrin homolog. |
Q24292698 | Contribution of p16INK4a and p21CIP1 pathways to induction of premature senescence of human endothelial cells: permissive role of p53 |
Q33609776 | Controlling the receptor for advanced glycation end-products to conquer diabetic vascular complications |
Q28168105 | Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins |
Q34427072 | Coronary microvascular dysfunction in diabetes mellitus: A review |
Q36938546 | Cross-susceptibility between periodontal disease and type 2 diabetes mellitus: an immunobiological perspective. |
Q26781156 | Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary management |
Q33786872 | DJC Suppresses Advanced Glycation End Products-Induced JAK-STAT Signaling and ROS in Mesangial Cells |
Q57549422 | Decreased plasma sRAGE levels in COPD: influence of oxygen therapy |
Q50227375 | Deficiency of the complement regulatory protein CD59 accelerates the development of diabetes-induced atherosclerosis in mice |
Q37202057 | Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice |
Q34024334 | Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse |
Q51550442 | Detection of Circulating Auto-Antibodies Against Ribosylated-LDL in Diabetes Patients. |
Q28344139 | Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice |
Q91754413 | Diabetes Mellitus and Cardiovascular Disease |
Q37333371 | Diabetes and atherosclerosis: is there a role for hyperglycemia? |
Q37486465 | Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions |
Q36744061 | Diabetes reduces aortic endothelial gap junctions in ApoE-deficient mice: simvastatin exacerbates the reduction |
Q53486855 | Diabetes with poor glycaemic control does not promote atherosclerosis in genetically modified hypercholesterolaemic minipigs. |
Q34470314 | Diabetes. |
Q45072634 | Diabetic Microvascular Disease: An Endocrine Society Scientific Statement |
Q30433016 | Diabetic conditions promote binding of monocytes to vascular smooth muscle cells and their subsequent differentiation |
Q42031332 | Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha |
Q36199128 | Diabetic vascular disease and the potential role of macrophage glucose metabolism |
Q34733351 | Diabetic vascular dysfunction: links to glucose-induced reductive stress and VEGF. |
Q36963380 | Dietary Advanced Glycation End Products and Their Potential Role in Cardiometabolic Disease in Children |
Q44474816 | Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice |
Q35895741 | Differential activation of RAGE by HMGB1 modulates neutrophil-associated NADPH oxidase activity and bacterial killing |
Q34399952 | Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin-treated, apolipoprotein E-deficient mice |
Q64259519 | Divergent Changes in Plasma AGEs and sRAGE Isoforms Following an Overnight Fast in T1DM |
Q39158946 | Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension? |
Q37941867 | Do statins have a role in reduction/prevention of post-PCI restenosis? |
Q64958363 | Dynamic fluctuations of advanced glycation end products and its C-terminal truncated receptor level in patients with acute ST-segment elevation myocardial infarction and undergoing diabetes or not: A retrospective study. |
Q37578319 | Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer's disease |
Q34362687 | Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients |
Q56905400 | Effects of Averrhoa bilimbi leaf extract on blood glucose and lipids in streptozotocin-diabetic rats |
Q45241682 | Effects of diabetes and CETP expression on diet-induced atherosclerosis in LDL receptor-deficient mice. |
Q64110582 | Efficacy of Co-administration of Liuwei Dihuang Pills and Ginkgo Biloba Tablets on Albuminuria in Type 2 Diabetes: A 24-Month, Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial |
Q53595048 | Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. |
Q36207823 | Emerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway. |
Q42176457 | Endogenous Secretory RAGE as a Novel Biomarker for Metabolic Syndrome and Cardiovascular Diseases. |
Q42406006 | Endothelial dysfunction and vascular inflammation in type 2 diabetes: interaction of AGE/RAGE and TNF-alpha signaling |
Q34747124 | Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation |
Q37216724 | Endothelium-specific GTP cyclohydrolase I overexpression accelerates refractory wound healing by suppressing oxidative stress in diabetes |
Q92848013 | Epigenetics and vascular diseases |
Q73668176 | Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays |
Q43059409 | Expression of S100A12 (EN-RAGE) in cystic fibrosis |
Q81810954 | Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs |
Q30873486 | FEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products. |
Q42227340 | Fibronectin glycation increases IGF-I induced proliferation of human aortic smooth muscle cells. |
Q37526511 | Flow patterns regulate hyperglycemia-induced subendothelial matrix remodeling during early atherogenesis |
Q34994616 | Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome. |
Q38258947 | Galectin-3: an emerging all-out player in metabolic disorders and their complications |
Q37607192 | GeneOptimizer program-assisted cDNA reengineering enhances sRAGE autologous expression in Chinese hamster ovary cells |
Q34080318 | Genetic modifiers of atherosclerosis in mice |
Q55043209 | Glycaemic control in type 2 diabetic patients with chronic kidney disease: the impacts on enzymatic antioxidants and soluble RAGE. |
Q38062900 | Glycated proteome: from reaction to intervention |
Q34006261 | Glycoxidation and lipoxidation in atherogenesis |
Q38221639 | Glycoxidation of biological macromolecules: a critical approach to halt the menace of glycation. |
Q95515700 | GnRH impairs diabetic wound healing through enhanced NETosis |
Q38939435 | HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins |
Q33930928 | High levels of IgM against methylglyoxal-modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes |
Q33592848 | Higher serum soluble receptor for advanced glycation end product levels and lower prevalence of metabolic syndrome among Japanese adult men: a cross-sectional study |
Q24795988 | How hyperglycemia promotes atherosclerosis: molecular mechanisms |
Q24530027 | Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice |
Q57817035 | Hyperglycemia Aggravates Diet-Induced Coronary Artery Disease and Myocardial Infarction in SR-B1-Knockout/ApoE-Hypomorphic Mice |
Q35830289 | Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes. |
Q55355643 | Hyperglycemia does not affect tissue repair responses in shear stress-induced atherosclerotic plaques in ApoE-/- mice. |
Q37711215 | Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis |
Q28260396 | Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein |
Q24682735 | Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation |
Q33556567 | Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands |
Q28360470 | Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model |
Q37768423 | Hyperoxia sensing: from molecular mechanisms to significance in disease |
Q36893819 | Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway |
Q53218782 | IL-1β enhances vascular smooth muscle cell proliferation and migration via P2Y2 receptor-mediated RAGE expression and HMGB1 release. |
Q37305013 | IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies |
Q28590453 | Identification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: structure, function and expression |
Q42013140 | Imaging RAGE expression in atherosclerotic plaques in hyperlipidemic pigs |
Q40979636 | Imaging receptor for advanced glycation end product expression in mouse model of hind limb ischemia |
Q42628303 | Immune activation resulting from NKG2D/ligand interaction promotes atherosclerosis |
Q37325024 | Immune and inflammatory mechanisms of atherosclerosis (*) |
Q37261617 | Immune mechanisms in atherosclerosis, especially in diabetes type 2 |
Q48511733 | Impact of diabetes on gingival wound healing via oxidative stress |
Q42672104 | Impact of hyperglycemia and acute pancreatitis on the receptor for advanced glycation endproducts |
Q50223052 | Impaired osteogenic differentiation and enhanced cellular receptor of advanced glycation end products sensitivity in patients with type 2 diabetes |
Q24337632 | In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced glycation end products (RAGE) |
Q35876768 | Increased levels of calprotectin in obesity are related to macrophage content: impact on inflammation and effect of weight loss |
Q34364237 | Induction of RAGE shedding by activation of G protein-coupled receptors |
Q34326241 | Inflammation in nonhealing diabetic wounds: the space-time continuum does matter |
Q36001244 | Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells |
Q27317653 | Inhibition of nuclear factor of activated T-cells (NFAT) suppresses accelerated atherosclerosis in diabetic mice |
Q27011696 | Insulin resistance, hyperglycemia, and atherosclerosis |
Q52544667 | Insulin-like growth factor II plays a central role in atherosclerosis in a mouse model. |
Q24323192 | Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42 |
Q46517192 | Interferon-gamma-inducible protein (IP)-10 mRNA stabilized by RNA-binding proteins in monocytes treated with S100b |
Q43907504 | Intra-peritoneal sRAGE treatment induces alterations in cellular distribution of CD19(+), CD3 (+) and Mac-1 (+) cells in lymphoid organs and peritoneal cavity |
Q30317651 | Intraoperative sRAGE kinetics. A new age-related outcome predictor of cardiac surgery |
Q36082148 | Introduction of hyperglycemia and dyslipidemia in the pathogenesis of diabetic vascular complications |
Q51446086 | Investigations on the reactions of α-dicarbonyl compounds with amino acids and proteins during in vitro digestion of biscuits. |
Q41789363 | Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy |
Q46468830 | Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells |
Q33918403 | Lack of the receptor for advanced glycation end-products attenuates E. coli pneumonia in mice |
Q26766350 | Large animal models of cardiovascular disease |
Q33344161 | Large scale isolation and purification of soluble RAGE from lung tissue |
Q77578272 | Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE) |
Q35944988 | Ligands of the receptor for advanced glycation end products, including high-mobility group box 1, limit bacterial dissemination during Escherichia coli peritonitis |
Q26795694 | Linking RAGE and Nox in diabetic micro- and macrovascular complications |
Q57182351 | Linking diabetes and atherosclerosis |
Q44517931 | Lipoprotein subclass profiles of hyperlipidemic diabetic mice measured by nuclear magnetic resonance spectroscopy |
Q42256397 | Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients |
Q57825219 | Low maternal serum matrix metalloproteinase (MMP)-2 concentrations are associated with preterm labor and fetal inflammatory response |
Q37437155 | Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes |
Q36478250 | Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling |
Q38586884 | MEMBRANE TYPE 1-MATRIX METALLOPROTEINASE (MT1-MMP) IDENTIFIED AS A MULTIFUNCTIONAL REGULATOR OF VASCULAR RESPONSES. |
Q38172884 | Macrophage-mediated glucolipotoxicity via myeloid-related protein 8/toll-like receptor 4 signaling in diabetic nephropathy |
Q37107174 | Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications |
Q22306395 | Mechanisms, Pathophysiology, and Therapy of Arterial Stiffness |
Q57131309 | Mechanistic targeting of advanced glycation end-products in age-related diseases |
Q37139800 | Mice deficient in PKCbeta and apolipoprotein E display decreased atherosclerosis |
Q35837912 | Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: a substudy of TALENT. |
Q64057969 | Modulation of soluble receptor for advanced glycation end-products (RAGE) isoforms and their ligands in healthy aging |
Q28070313 | Molecular Imaging of Vulnerable Atherosclerotic Plaques in Animal Models |
Q26782445 | Molecular Pathways Regulating Macrovascular Pathology and Vascular Smooth Muscle Cells Phenotype in Type 2 Diabetes |
Q36139535 | Mouse Specific Cleavage-Resistant RAGE Splice Variant |
Q36766171 | Mouse models for studies of cardiovascular complications of type 1 diabetes |
Q59133666 | Multimodal imaging of the receptor for advanced glycation end-products with molecularly targeted nanoparticles |
Q37564063 | Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications |
Q64076770 | Myocardial Ischemia and Diabetes Mellitus: Role of Oxidative Stress in the Connection between Cardiac Metabolism and Coronary Blood Flow |
Q44357475 | N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. |
Q37036184 | N(epsilon)-(Carboxymethyl)lysine and Coronary Atherosclerosis-Associated Low Density Lipoprotein Abnormalities in Type 2 Diabetes: Current Status. |
Q36297295 | N-butanol extracts of Morinda citrifolia suppress advanced glycation end products (AGE)-induced inflammatory reactions in endothelial cells through its anti-oxidative properties |
Q54682072 | NBRI17671, a new antitumor compound, produced by Acremonium sp. CR17671. |
Q38227386 | NF-κB signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links |
Q43687605 | Non-obese diabetic (NOD) mice exhibit an increased cellular immune response to glycated-LDL but are resistant to high fat diet induced atherosclerosis |
Q29616101 | Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage |
Q37990618 | Novel pathways and therapies in experimental diabetic atherosclerosis |
Q38359414 | Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury |
Q30993051 | O-glycosylation regulates ubiquitination and degradation of the anti-inflammatory protein A20 to accelerate atherosclerosis in diabetic ApoE-null mice |
Q44640723 | Oleate, not ligands of the receptor for advanced glycation end-products, promotes proliferation of human arterial smooth muscle cells |
Q80362512 | Oxidative stress and diabetic vascular complications |
Q36204491 | Oxidative stress and stress signaling: menace of diabetic cardiomyopathy |
Q36891939 | Oxidative stress, AGE, and atherosclerosis |
Q43109146 | Oxidative stress-associated rise of hepatic protein glycation increases inflammatory liver injury in uncoupling protein-2 deficient mice |
Q37397476 | PKCβ promotes vascular inflammation and acceleration of atherosclerosis in diabetic ApoE null mice |
Q28362804 | PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice |
Q34766912 | Paradoxical function for the receptor for advanced glycation end products in mouse models of pulmonary fibrosis |
Q37494520 | Pathogenesis and pathophysiology of accelerated atherosclerosis in the diabetic heart. |
Q42812060 | Pathological roles of advanced glycation end product receptors SR-A and CD36. |
Q36065338 | Pathophysiology and Medical Treatment of Carotid Artery Stenosis |
Q34018425 | Percutaneous treatment of peripheral vascular disease: the role of diabetes and inflammation |
Q43911870 | Periodontal disease and diabetes mellitus: discussion, conclusions, and recommendations |
Q59804720 | Periodontal regenerative effect of enamel matrix derivative in diabetes |
Q30309168 | Pimagedine: a novel therapy for diabetic nephropathy |
Q30253065 | Plasma Soluble Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis |
Q37176678 | Plasma levels of soluble receptor for advanced glycation end products and coronary atherosclerosis: possible correlation with clinical presentation. |
Q33723012 | Plasma levels of the pro-inflammatory protein S100A12 (EN-RAGE) are associated with muscle and fat mass in hemodialysis patients: a cross-sectional study |
Q38197360 | Possible role of methylglyoxal and glyoxalase in arthritis |
Q74708419 | Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure |
Q57825168 | Pregnancy-associated plasma protein A (PAPP-A) and soluble receptor for advanced glycation end products (sRAGE) – intra- and inter-individual variability in chronic hemodialysis patients |
Q36108353 | Preserved DNA Damage Checkpoint Pathway Protects against Complications in Long-Standing Type 1 Diabetes |
Q28508886 | Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE) |
Q47730385 | Pyridoxamine: A novel treatment for schizophrenia with enhanced carbonyl stress |
Q60732952 | RAGE Gene Polymorphisms in Patients with Multiple Sclerosis |
Q35102969 | RAGE Signaling Significantly Impacts Tumorigenesis and Hepatic Tumor Growth in Murine Models of Colorectal Carcinoma |
Q35740332 | RAGE Suppresses ABCG1-Mediated Macrophage Cholesterol Efflux in Diabetes |
Q37455857 | RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation? |
Q44032299 | RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response |
Q36320548 | RAGE and its ligands: a lasting memory in diabetic complications? |
Q36756482 | RAGE and modulation of ischemic injury in the diabetic myocardium |
Q36969021 | RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases |
Q48536125 | RAGE binds preamyloid IAPP intermediates and mediates pancreatic β cell proteotoxicity. |
Q37860348 | RAGE biology, atherosclerosis and diabetes |
Q36635410 | RAGE deficiency improves postinjury sciatic nerve regeneration in type 1 diabetic mice |
Q42263637 | RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy |
Q41243867 | RAGE inhibition reduces acute lung injury in mice. |
Q41853060 | RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB |
Q22010236 | RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides |
Q28482199 | RAGE mediates accelerated diabetic vein graft atherosclerosis induced by combined mechanical stress and AGEs via synergistic ERK activation |
Q46142346 | RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice |
Q33559727 | RAGE modulates hypoxia/reoxygenation injury in adult murine cardiomyocytes via JNK and GSK-3beta signaling pathways. |
Q46775210 | RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model |
Q52857005 | RAGE polymorphisms and the heritability of insulin resistance: the Leeds family study. |
Q33646761 | RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice |
Q33346824 | RAGE signaling in inflammation and arterial aging |
Q49413376 | RAGE-aptamer attenuates deoxycorticosterone acetate/salt-induced renal injury in mice |
Q27025295 | RAGE: a new frontier in chronic airways disease |
Q35854488 | RAGE: a novel target for drug intervention in diabetic vascular disease |
Q51061874 | Racial differences in circulating levels of the soluble receptor for advanced glycation endproducts in middle-aged and older adults. |
Q47118560 | Raman spectroscopy imaging reveals interplay between atherosclerosis and medial calcification in the human aorta. |
Q37181988 | Reactive immunization suppresses advanced glycation and mitigates diabetic nephropathy |
Q37384331 | Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response |
Q37972674 | Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications |
Q90643374 | Receptor for Advanced Glycation End Products (RAGE) and Mechanisms and Therapeutic Opportunities in Diabetes and Cardiovascular Disease: Insights From Human Subjects and Animal Models |
Q37997993 | Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure |
Q36842628 | Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes |
Q40899986 | Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response |
Q22010208 | Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways |
Q21285070 | Receptor for advanced glycation end products and its involvement in inflammatory diseases |
Q36203962 | Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis |
Q30378823 | Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia. |
Q41884655 | Receptor for advanced glycation end products regulates adipocyte hypertrophy and insulin sensitivity in mice: involvement of Toll-like receptor 2 |
Q41926813 | Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis |
Q37373486 | Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. |
Q34586849 | Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes |
Q43090705 | Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity |
Q34188756 | Receptor for advanced glycation endproducts mediates pro-atherogenic responses to periodontal infection in vascular endothelial cells |
Q35009768 | Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings |
Q22254188 | Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis |
Q36605862 | Reduced soluble RAGE is associated with disease severity of axonal Guillain-Barré syndrome |
Q37400729 | Reductive metabolism of AGE precursors: a metabolic route for preventing AGE accumulation in cardiovascular tissue |
Q35494903 | Regulation of RAGE for attenuating progression of diabetic vascular complications |
Q38782723 | Regulation of Receptor for Advanced Glycation End Products (RAGE) Ectodomain Shedding and Its Role in Cell Function. |
Q44499434 | Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products |
Q40541205 | Regulation of inducible nitric oxide synthase expression in advanced glycation end product-stimulated raw 264.7 cells: the role of heme oxygenase-1 and endogenous nitric oxide |
Q34321457 | Regulation of ligands for the NKG2D activating receptor |
Q38523267 | Role of Advanced Glycation End Products and Its Receptors in the Pathogenesis of Cigarette Smoke-Induced Cardiovascular Disease |
Q35610210 | Role of HMGB1 in cardiovascular diseases |
Q35929112 | Role of advanced glycation end products in cardiovascular disease. |
Q36416215 | Role of diabetes in atherosclerotic pathogenesis. What have we learned from animal models? |
Q46555270 | Role of soluble receptor for advanced glycation end products on endotoxin-induced lung injury. |
Q24318401 | S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells |
Q36631781 | S100A12 and the S100/Calgranulins: Emerging Biomarkers for Atherosclerosis and Possibly Therapeutic Targets |
Q33984573 | S100B Serum Levels in Schizophrenia Are Presumably Related to Visceral Obesity and Insulin Resistance |
Q37837904 | S100B protein in neurodegenerative disorders |
Q52666460 | SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr-/- type 1 diabetic mice. |
Q47879810 | Secretogranin III: a diabetic retinopathy-selective angiogenic factor. |
Q37300540 | Senescence-dependent impact of anti-RAGE antibody on endotoxemic liver failure |
Q46126412 | Serum advanced glycation end products (AGEs) are associated with insulin resistance |
Q35844102 | Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes |
Q80478922 | Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects |
Q37729101 | Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(-/-) mice by downregulating the HMGB1-RAGE axis |
Q37740359 | Skin Autofluorescence is Associated with Early-stage Atherosclerosis in Patients with Type 1 Diabetes |
Q37158807 | Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events |
Q35077903 | Skin autofluorescence, a non-invasive marker for AGE accumulation, is associated with the degree of atherosclerosis |
Q27319831 | Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice. |
Q36091982 | Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study |
Q40126438 | Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified low-density lipoprotein |
Q54605224 | Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease. |
Q34094369 | Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging |
Q26780488 | Soluble Receptor for Advanced Glycation End Product: A Biomarker for Acute Coronary Syndrome |
Q82511623 | Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictor of Restenosis Following Percutaneous Coronary Intervention |
Q64912818 | Soluble receptor for AGE in diabetic nephropathy and its progression in Finnish individuals with type 1 diabetes. |
Q61845347 | Soluble receptor for advanced glycation end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: modulation by infection and inflammation |
Q39636114 | Soluble receptor for advanced glycation end products (sRAGE) is present at high concentrations in the lungs of children and varies with age and the pattern of lung inflammation. |
Q51620241 | Soluble receptor for advanced glycation end products and increased aortic stiffness in the general population. |
Q36263332 | Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study |
Q34774357 | Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study |
Q33613288 | Soluble receptor for advanced glycation end-products and progression of airway disease |
Q90859382 | Soluble receptor for advanced glycation end-products independently influences individual age-dependent increase of arterial stiffness |
Q48100352 | Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: New Roles for Soluble RAGE. |
Q38795678 | Solution structure of the soluble receptor for advanced glycation end products (sRAGE). |
Q35086814 | Spontaneously diabetic Ins2(+/Akita):apoE-deficient mice exhibit exaggerated hypercholesterolemia and atherosclerosis |
Q27678167 | Stable RAGE-Heparan Sulfate Complexes Are Essential for Signal Transduction |
Q39106836 | Statins stimulate the production of a soluble form of the receptor for advanced glycation end products |
Q27665039 | Structural Basis for Ligand Recognition and Activation of RAGE |
Q40668935 | Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system |
Q46061259 | Synergistic vasculogenic effects of AMD3100 and stromal-cell-derived factor-1α in vasa nervorum of the sciatic nerve of mice with diabetic peripheral neuropathy |
Q73653690 | Synthesis and reactivity of the monosaccharide esters of amino acids as models of teichoic acid fragment |
Q34415503 | TP receptors and oxidative stress hand in hand from endothelial dysfunction to atherosclerosis |
Q60923225 | Targeted nanoparticles for multimodal imaging of the receptor for advanced glycation end-products |
Q37424029 | Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation |
Q47094524 | The AGE-RAGE Axis: Implications for Age-Associated Arterial Diseases |
Q37091107 | The AGE/RAGE axis in diabetes-accelerated atherosclerosis. |
Q36139994 | The Mouse-Specific Splice Variant mRAGE_v4 Encodes a Membrane-Bound RAGE That Is Resistant to Shedding and Does Not Contribute to the Production of Soluble RAGE. |
Q37355646 | The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth |
Q33822512 | The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature |
Q37560012 | The Role of Immunogenicity in Cardiovascular Disease |
Q41729219 | The association between the RAGE G82S polymorphism, sRAGE and chronic periodontitis in Taiwanese individuals with and without diabetes. |
Q48359381 | The association of low muscle mass with soluble receptor for advanced glycation end products (sRAGE): The Korean Sarcopenic Obesity Study (KSOS). |
Q33615012 | The attenuation of Moutan Cortex on oxidative stress for renal injury in AGEs-induced mesangial cell dysfunction and streptozotocin-induced diabetic nephropathy rats |
Q36787569 | The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications |
Q34100112 | The biology of the receptor for advanced glycation end products and its ligands |
Q34271106 | The contribution of mitochondria to common disorders |
Q38023062 | The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. |
Q42849056 | The effects of the receptor for advanced glycation end products (RAGE) on bone metabolism under physiological and diabetic conditions |
Q36857011 | The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. |
Q73788217 | The functions of circulatory polymorphonuclear leukocytes in diabetic patients with and without diabetic triopathy |
Q28570659 | The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells |
Q36461096 | The ligand/RAGE axis: lighting the fuse and igniting vascular stress |
Q34387881 | The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses |
Q28830568 | The multiple faces of RAGE--opportunities for therapeutic intervention in aging and chronic disease |
Q41879957 | The next generation of RAGE modulators: implications for soluble RAGE therapies in vascular inflammation |
Q42037633 | The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment |
Q57718003 | The possible role of esRAGE and sRAGE in the natural history of diabetic nephropathy in childhood |
Q59340735 | The ratio of AGE to sRAGE independently associated with albuminuria in hypertensive patients |
Q38025026 | The receptor for advanced glycation end products and acute lung injury/acute respiratory distress syndrome |
Q40877248 | The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells |
Q37412673 | The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease |
Q35649410 | The role of advanced glycation end products in the development of atherosclerosis |
Q37860412 | The role of receptor for advanced glycation endproducts (RAGE) in infection |
Q37464743 | Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials |
Q48101313 | Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes |
Q53258066 | Tissue-specific expression patterns of the RAGE receptor and its soluble forms—a result of regulated alternative splicing? |
Q90366910 | Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis |
Q33700652 | Triglyceride-rich lipoproteins: are links with atherosclerosis mediated by a procoagulant and proinflammatory phenotype? |
Q46495572 | Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients |
Q36245387 | Understanding RAGE, the receptor for advanced glycation end products |
Q38134924 | Unlocking the biology of RAGE in diabetic microvascular complications |
Q80968903 | Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis |
Q36514906 | Uremic Toxicity of Advanced Glycation End Products in CKD. |
Q35903021 | Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting RAGE Signaling in Diabetic Atherosclerosis |
Q30444108 | Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice |
Q36537262 | Vascular complications of diabetes: mechanisms of injury and protective factors |
Q37636453 | Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms |
Q34498985 | Vessel ultrasound sonographic assessment of soluble receptor for advanced glycation end products efficacy in a rat balloon injury model |
Q39951404 | Why does diabetes increase atherosclerosis? I don't know! |
Q83105602 | [Current concepts of diabetic atherogenesis] |
Q30318169 | [Protein glycation as a pathological mechanism in diabetes]. |
Q36867450 | sRAGE and risk of diabetes, cardiovascular disease, and death |
Q36070548 | sRAGE in diabetic and non-diabetic critically ill patients: effects of intensive insulin therapy |
Q36900801 | sRAGE induces human monocyte survival and differentiation |
Search more.